3.27
+6.17%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Mayne Pharma Group
Its shares trade on ASX under the ticker MYX.AX. It has been listed since 29 June 2007. In the fiscal year to 30 June 2026, it reported revenue of A$383.7m and net income of A$24.5m. At that date it held total assets of A$909.4m and shareholders' equity of A$390.9m.
Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. The company is headquartered in Adelaide, South Australia. The company went IPO on 2007-06-29. The firm is focused on commercializing branded and generic pharmaceuticals. The company operates through four segments: Generic Products (GPD), Specialty Brands (SBD), Metrics Contract Services (MCS) and Mayne Pharma International (MPI). The GPD segment is engaged in the manufacture and distribution of generic pharmaceutical products in the United States. The SBD segment markets and distributes specialty branded pharmaceutical products in the United States. The MCS segment is engaged in the provision of contract analytical and pharmaceutical development services to third-party customers in the United States. The MPI segment is engaged in Australian manufacture and sale of branded and generic pharmaceutical product globally and provision of contract manufacturing services to third-party customers within Australia.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 29 Jun 2007
- Employees
- 850
- Website
- maynepharma.com ↗
Leadership
Pay as last reported
- Mr. Frank CondellaNon-Executive Independent Chairman of the BoardA$305,398
- Mr. Shawn O' BrienChief Executive Officer, Managing Director, Executive Director, since 2022A$2.1m
- Mr. Aaron GrayChief Financial OfficerA$1.3m
- Ms. Laura LoftusCompany Secretary
- Mr. David PetrieNon-Executive DirectorA$217,862
- Mr. Patrick BlakeIndependent Non-Executive DirectorA$218,360
- Ms. Ann CustinIndependent Non-Executive DirectorA$235,157
- Ms. Anne LockwoodIndependent Non-Executive DirectorA$117,493
- Dr. Kathryn MacfarlaneIndependent Non-Executive DirectorA$215,835
- Prof. Bruce RobinsonIndependent Non-Executive DirectorA$219,385
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 52
- Environment
- 32
- Social
- 99
- Governance
- 26
- Women in the workforce
- 51%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Mayne Pharma Group Ltd possesses several strengths that contribute to its competitive advantage in the pharmaceutical industry. Firstly, it has a robust portfolio of products, including both branded and generic drugs, which caters to a diverse range of therapeutic areas. This broad offering strengthens the company's market positioning and allows for revenue diversification.
- Secondly, Mayne Pharma has a strong research and development division, enabling them to develop innovative formulations and improve existing products. This capability enhances their ability to meet evolving customer needs and differentiate themselves in the market.
- Thirdly, the company has a global presence, with a solid footprint in various markets. This international reach provides Mayne Pharma with opportunities for revenue growth, market expansion, and potential partnerships.
Weaknesses
- Despite its strengths, Mayne Pharma also faces a few weaknesses that need to be addressed. Firstly, the company heavily relies on a few key products for a significant portion of its revenue. This concentration poses risks, as any decline in sales or competition in those specific products could impact overall financial performance.
- Secondly, Mayne Pharma's manufacturing capabilities have faced quality issues in the past, resulting in regulatory actions. These incidents have the potential to harm the company's reputation and increase compliance costs.
- Lastly, compared to some larger competitors, Mayne Pharma has relatively limited financial resources. This could limit their ability to invest in research and development or pursue strategic acquisitions to expand their product portfolio.
Opportunities
- Mayne Pharma operates in an industry with several growth opportunities. Firstly, the increasing global demand for pharmaceutical products, driven by an aging population and rising healthcare needs, presents a favorable market environment for the company to expand its sales.
- Secondly, the growing trend towards specialty pharmaceuticals and personalized medicine opens up avenues for Mayne Pharma to develop targeted therapies and establish themselves as a leader in specific disease areas.
- Moreover, the company can explore partnerships or licensing agreements with research institutions or other pharmaceutical firms to leverage their expertise and enhance their product pipeline.
Threats
- Mayne Pharma faces various threats that could impact its performance. Firstly, intense competition within the pharmaceutical industry can limit market share and pricing power, potentially leading to reduced profitability. The presence of both domestic and international competitors further intensifies this rivalry.
- Secondly, regulatory changes or stricter enforcement could increase compliance costs and add complexities to the approval process for new products or manufacturing facilities.
- Lastly, macroeconomic factors, such as fluctuations in exchange rates or changes in government healthcare policies, may affect the affordability and accessibility of pharmaceutical products, potentially impacting Mayne Pharma's sales and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.